Individuals with low levels of mannan-binding lectin (MBL) appear to be susceptible to infectious diseases. This suggests that substitution therapy with MBL might be a beneficial treatment of patients with MBL deficiency. A production process for an MBL product has been developed from a fraction II+III precipitate obtained by ethanol fractionation of plasma. The MBL process includes three chromatographic steps, where the first and key step is affinity chromatography on a cross-linked agarose matrix selecting for oligomeric, carbohydrate-binding MBL. The yield from the production process is about 25% of the plasma MBL content, and the purity is about 65%. The MBL product shows mannan-binding activity and complement-activating ability. A safety study has shown this plasma-derived MBL to be safe and well tolerated in adult MBL-deficient volunteers.
Skip Nav Destination
Conference Article| August 01 2003
Mannan-binding lectin (MBL) production from human plasma
Publisher: Portland Press Ltd
Online ISSN: 1470-8752
Print ISSN: 0300-5127
© 2003 Biochemical Society
Biochem Soc Trans (2003) 31 (4): 758–762.
I. Laursen; Mannan-binding lectin (MBL) production from human plasma. Biochem Soc Trans 1 August 2003; 31 (4): 758–762. doi: https://doi.org/10.1042/bst0310758
Download citation file:
Don't already have an account? Register
Get Access To This Article
Buy This Article